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Oral route maintains its predominance among the ones used for drug delivery, especially 
when medicines are self-administered. If the dosage form is solid, therapy gains in 
dose precision and drug stability. Yet, some active pharmaceutical substances do 
not present the required solubility, permeability, or release profile for incorporation into 
traditional matrices. The combination of nanostructured drugs (nanoparticle [NP]) with 
these matrices is a new and little-explored alternative, which could bring several benefits. 
Therefore, this review focused on combined delivery systems based on nanostructures 
to administer drugs by the oral cavity, intended for buccal, sublingual, gastric, or 
intestinal absorption. We analyzed published NP-in-matrix systems and compared main 
formulation characteristics, pharmacokinetics, release profiles, and physicochemical 
stability improvements. The reported formulations are mainly semisolid or solid polymers, 
with polymeric or lipid NPs and one active pharmaceutical ingredient. Regarding drug 
specifics, most of them are poorly permeable or greatly metabolized. The few studies with 
pharmacokinetics showed increased drug bioavailability and, sometimes, a controlled 
release rate. From our knowledge, the gathered data make up the first focused review of 
these trendy systems, which we believe will help to gain scientific deepness and future 
advancements in the field.
Keywords: nanoparticle, oral delivery, buccal delivery, matrix delivery, drug absorption
INTRODUCTION
Medicines administered by the oral cavity have different fates, according to their varied processes: 
(i) immediate delivery and absorption, (ii) slow delivery from an adherent drug delivery system 
(DDS), followed by absorption or local action; and (iii) transport to the gastrointestinal region for 
absorption or local action. The latter is the gold standard for medicines and the most common 
process used for self-administered drug intake. Recently, buccal permeation (items i and ii) strategies 
increased in number of developments; this route bypasses hepatic and gastrointestinal effects, which 
is advantageous to sensitive drugs (Barua et al., 2016).
Regardless of the process, drug solubility can impair efficient release from DDS and subsequent 
mucosal crossing. Therefore, several solubilization strategies are available, such as salt forms of 
active molecules, pH modifiers, cosolvents, amorphization, solid dispersions, inclusion complexes, 
microemulsions, and nanotechnology (Kalepu and Nekkanti, 2015). The latter represents a large 
portion of published research but a few marketed products and no buccal-based options.
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In addition to the solubility enhancement, nanoparticles (NPs) 
aid drug efficacy in at least four different ways (Figure 1). The 
simpler way relates to transport throughout the gastrointestinal 
lumen and local release (mode 1). Another possibility consists of 
carrier adherence to the mucosal surface/mucus to enhance drug 
absorption, but without carrier crossing (mode 2). Nanoparticles 
may also be absorbed and transport the drug systemically, 
enhancing its plasma half-life (mode 3). Absorbed NPs can 
then perform passive targeting due to charge, size, morphology, 
and constituents. For a detailed review on mechanisms of NP/
absorption and uptake, see Griffin et al. (2016). Mode 4 happens 
when specific surface molecules or pH-responsive mechanisms 
allow the carrier to perform an active targeting after absorption. 
Modes 3 and 4 can still avoid first-pass metabolism if absorption 
happens in the buccal mucosa or lymphatic vessels. However, 
like other delivery strategies, NPs can fail to liberate drugs at an 
expected rate or target, as described in the following paragraphs.
For drug uptake enhancement, NPs need to interact with the 
respective mucosal surface/mucus during an adequate amount of 
time. Some particles do stick to mucosa under continuous rinsing, 
such as thiolated chitosan NPs. But, in this case, NPs were freeze 
dried and applied on top of the mucosa in an ex vivo test (Bernkop-
Schnürch et al., 2006). Since powder formulations require specific 
devices or encapsulation for a precise dosage, they generally 
require an additional delivery strategy to be administered.
A noteworthy NP disadvantage is the burst effect: a rapid initial 
drug release followed by a sustained or controlled release. Rapid 
plasma peaks or local drug concentration are desirable in some 
therapies; however, burst behavior is frequently uncontrollable and 
irreproducible. The phenomenon occurs due to several reasons, 
including weakly bound drugs, molecule migration to the particle 
surface, and nanomatrix heterogeneity (Kamaly et  al., 2016). 
Strategies to prevent it include coating or nanomatrix reformulation 
(Kamaly et al., 2016), not always straightforward because both 
processes change NP physicochemical characteristics.
The majority of oral DDSs are biodegradable, so they will erode or 
degrade at some point. In fact, some systems rely on both properties 
as a release mechanism. If the carrier liberates as desired, it may 
not be resistant to pH/enzymes during traffic or at the action site. 
An earlier instability may interfere with the desired drug liberation 
profile, such as for regular gelatin NPs: their degradation in the 
stomach requires coating, chemical modification or an outermatrix 
embedment to allow intestinal release (Imperiale and Sosnik, 2013).
Apart from degradation, NPs can change their fate, uptake, 
or release rate due to in vitro or in vivo aggregation. The in vitro 
facet shows that cell media for cell culture is quite different from 
lumen or saliva environments, which makes it hard to predict 
aggregation during in vivo absorption (Moore et al., 2015).
All failure modes described above can be solved or attenuated 
with NP dispersion in micromatrices and macromatrices (Figure 2), 
reasons why this technique became important for buccal and oral 
delivery. As opposed to coating and core modifications, matrix 
embedment brings an extra added value: it can be applied to several 
kinds of NPs, with a better general prediction of the release behavior.
Considering all points above, this review intends to analyze 
pharmacokinetic improvements with the use of NPs incorporated 
in matrices for drug delivery (NP-in-matrix). Therefore, we 
focused here on pharmacokinetic data from animal and humans 
(when available). Several NP-in-matrix systems were tested only 
with in vitro assays. However, correlation of in vivo behavior is 
not guaranteed, and an extensive array of protocols impairs model 
comparisons (discussed in the following topic). Combined systems 
resulting in nanosized carriers (NP-in-NP) were not included in 
this work. Based on the theoretical analysis, we intend to verify and 
clarify matrix role on permeation and bioavailability of nanocarriers.
PHARMACOKINETICS AND EVALUATION 
MODES FOR ORAL AND BUCCAL 
ADMINISTRATION
Pharmacokinetics describes absorption, distribution, metabolism, 
and excretion processes after drug intake. This knowledge remains 
essential for safety and efficacy assessments of the therapy in 
FIGURE 1 | Scheme (not to scale) of drug (blue circles) loaded nanoparticles 
(NPs, yellow circles) interacting with physiological environments. Nanoparticle 
modes to enhance drug systemic delivery through the oral or buccal routes. 
1: Lumen release (solubility enhancement), followed by NP excretion or 
degradation. 2: Adherence to mucus or mucosal surface for enhanced drug 
absorption (no NP permeation), followed by NP excretion or degradation. 
3: NP absorption for enhanced plasma half-life, followed by NP liver 
degradation or lymphatic drainage. 4: Tissue or cell targeting. Figure created 
for this review in CorelDRAW Graphics Suite X7.
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the search for the optimal DDS. However, in vivo tests must 
be a final step toward product development. It should succeed 
an extensive physicochemical characterization, together with 
promising in vitro data assessing biorelevant properties. Table 1 
lists the most common assays used to evaluate and predict in vivo 
parameters related to pharmacokinetics, together with drug and 
NP predictors. Because matrix-based formulations aid mainly in 
absorption, this process will be discussed in more detail below.
Nanoparticle permeation happens only after mucus barrier 
crossing (gastrointestinal) and subsequent cellular uptake for 
transcytosis (M cells, enterocytes) or paracellular transport. 
In vivo absorption is generally better predicted by ex vivo mucosal 
permeation than in vitro tests with synthetic membranes; the 
extracted tissue offers a biochemical, anatomical, and structural 
resemblance to its in vivo counterpart that is difficult to replicate 
(Berben et al., 2018).
When it comes to gastrointestinal absorption, Caco-2 cell 
model stands out among the options, joining cell layer with 
synthetic membrane permeation. This system is frequently used 
to classify drugs in a permeation rank to direct dosage form 
development. However, a review covering Caco-2 correlation with 
in vivo intestinal permeability stressed the test fragility. Based on 
several studies, the authors concluded that the model is applicable 
to hydrophobic drugs but fails to predict hydrophilic molecule 
absorption. Even with hydrophobic drugs, variability is high yet 
minimized with internal standards. The paracellular route and 
active transport seem to correlate with higher variability and in 
vivo–in vitro lack of correlation (Larregieu and Benet, 2013).
Regardless of the in vitro–ex vivo model, most of them do not 
promote predigestion of samples. One cannot estimate the effect 
of gastrointestinal fluids upon NPs without this assessment. 
Even nondegradable polystyrene NPs (unmodified, aminated, 
or carboxylated) promoted different ex vivo permeation profiles 
with predigestion, showing its relevance for in vivo prediction 
(Westerhout et al., 2017).
Drug/NP in vivo absorption can be estimated by plasma 
detection if metabolism does not influence their integrity. 
In vivo pharmacokinetics focuses on blood sampling and drug 
quantification at several time points, generally with rats, rabbits, 
or humans. The most common parameters include the amount 
of drug detected over time (area under the curve [AUC]), 
FIGURE 2 | Scheme (not to scale) of the failure modes of nanoparticles (NPs, 
yellow circles) loaded with drug (blue circles) after oral/buccal administration: 
early washout in mouth or intestinal cavities; early degradation due to pH or 
enzymes; burst release upon contact with aqueous media (saliva, stomach 
acid); aggregation due to pH, osmotic environment, and protein binding. 
The network on the left shows matrix protection through adhesion (wash 
out elimination), shielding (degradation and burst elimination/decrease), and 
physical separation (aggregation elimination). Figure created for this review in 
CorelDRAW Graphics Suite X7 and Adobe Photoshop CS6.
TABLE 1 | Pharmacokinetic parameters and evaluation strategies for oral/buccal medicines.
In vivoa Drug predictors NP predictors In vitro assays/ex vivo assays
Absorption T max, AUC, Cmax Solubility, lipophilicity (log P), 
molecular weight, number of 
hydrogen bond donor groups 
(Lipinski et al., 2001), log D, 
polar surface area and pKa 
(Berben et al., 2018)b
Charge, size, 
bioadhesiveness, lipophilicity, 
surface modification (Griffin 
et al., 2016)
Parallel artificial membrane permeation assay 
(PAMPA) and derivatives (Berben et al., 2018), 
cell based assays (mainly Caco-2), USP 
dissolution methods/derivativesc, permeation 
through mucosal tissue (pig, human)
Distribution Volume of drug distribution 
at steady state, 
tissue- plasma partition 
coefficients
logP, pKa Targeting ligands Plasma protein binding assay, ex vivo tissue 
distribution
Metabolism Metabolites in blood, 
urine, feces
ligand for liver enzymes, 
dlipophilicity
Targeting ligands, size, 
charge, lipophilicity, surface 
modification (Griffin et al., 
2016)
Metabolic activity of hepatocytes, cytochrome 
P450 (CYP) inhibition assay, liver and 
intestinal microsome stability
Excretion Drug in urine, feces Molecular weight, lipophilicity, 
pKa
Size Plasma protein binding
aIn vivo models include generally mice, rat, rabbit, dog, or monkey species. Monkeys are considered more reliable than other animal species to infer human pharmacokinetic profiles 
(Furukawa et al., 2014). bDrugs that are substrates for biological transporters do not present predictive permeability with only these parameters. cUSP dissolution methods vary 
depending on the dosage form. They can be predictive for drug with dissolution rate-limited absorption, but complex release kinetics and NP environmental changes may increase 
in vivo correlation failure. dTo check ligand properties, the most common method is molecular docking (Meng et al., 2011).
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the highest drug level detected (Cmax), and the time the latter 
happened (tmax). On the other hand, NPs are seldom classified 
based on plasma levels. Nanoparticle tracking relies mainly on 
marked particles with fluorescent dyes to observe biodistribution 
in tissues. An important reminder is that plasma levels do not 
discriminate buccal from gastric or intestinal absorption.
NP-IN-MATRIX DDSS
The following items present a discussion of all articles we 
could find with in vivo pharmacokinetic data of NP-in-matrix 
DDSs. The NP type directed subdivisions based on their main 
constituent. Exact values and formulation details are presented 
in Table 2.
Polymeric NPs
Polymers vary on their degradation, polarity, source, and chain 
size properties (Hallan et al., 2016). Polymeric based NPs 
present scalable manufacturing methods and capability to load 
a wide range of drug types (Crucho and Barros, 2017). The 
most common natural polymers for NPs are chitosan, sodium 
alginate, dextran, gelatin, and albumin. These hydrophilic 
proteins and carbohydrates degrade in physiological conditions, 
besides their biocompatibility, which helps to avoid side effects 
(Boateng and Areago, 2014; Madkhali et al., 2019; Bronze-Uhle 
et al., 2017; Kim et al., 2001). Alginate and chitosan still exhibit 
bioadhesive nature, which increases NP efficacy for mucosal 
delivery (Boateng and Areago, 2014). In turn, albumin discharges 
drugs via desorption without significant burst effects (Jiang and 
Stenzel, 2016). We have not found any pharmacokinetics data for 
NP-in-matrix systems based on gelatin or chitosan NPs; however, 
several studies discussed in this article address these excipients as 
matrix components.
Concerning alginate NPs, Garhy et al. loaded carvedilol 
in these carriers and further incorporated this system in 
buccoadhesive gels. The in vitro release assay showed burst 
behavior for all 12 different NP formulations. However, NP-in-
gel formulations (FG1 and FG2) indicated that the gelling agent 
delayed carvedilol release, which diminished burst. FG1 gel 
contained hydroxypropyl methylcellulose (HPMC), whereas 
le FG2 presented the same HPMC concentration and sodium 
carboxymethylcellulose. Rabbits treated with FG2 formulation 
showed a two-fold increase in relative bioavailability compared 
to the market product. The increase in bioavailability occurred 
probably due to NP enhancement in drug solubility and the 
buccal bypass of the first-pass effect (Garhy et al., 2018).
Albumin properties were tested in exenatide-loaded bovine 
serum albumin/dextran NPs; the peptide was adsorbed to the 
carrier protein and released in a sustained manner due to dextran 
crosslinkings. This loaded NP was incorporated in gastroresistant 
microparticles of Eudragit L/HPMC. The incorporation led to 
macromolecule protection and decreased release rates of the 
peptide cargo. Consequently, pharmacokinetic data showed that 
NP-in-matrix resulted in a high relative oral bioavailability of 
77% compared to a subcutaneous injection of the commercial 
equivalent medicine (Soudry-Kochavi et al., 2015).
Among the synthetic polymers, the aliphatic polyesters and 
their copolymers are the most used for drug delivery because 
of their biodegradability and biocompatibility. One of the most 
popular is the poly(lactic acid), often combined with glycolide 
to form the hydrophobic copolymer poly(lactic-co-glycolic acid) 
(PLGA) (Washington et al., 2017); PLGA exhibit high stability 
in biological fluids and long clinical experience; it was the only 
synthetic polymer to compose a nanostructure part of an NP-in-
matrix dosage form with pharmacokinetic data. All the drugs 
entrapped into these studied systems are considered poorly 
water-soluble drugs.
Three different studies reported buccal films as matrices 
for PLGA NPs. The incorporated drugs were acyclovir 
(Al-Dhubiab et al., 2015), selegiline (Al-Dhubiab, 2016a) and 
zolpidem (Al-Dhubiab, 2016b). In vitro studies showed that 
film formulations prolonged drug liberation in a composition-
dependent mode. The results of ex vivo studies with rabbit 
buccal mucosa showed that these nanospheres can permeate the 
tissue. In vivo results confirmed the predictions, whereas male 
rabbits demonstrated an increased drug bioavailability with the 
NP-in-film strategy. After incorporating NPs in polymeric films, 
the bioadhesive properties increased the residence time in oral 
cavity. It was also observed that Cmax, AUC, and tmax improved 
with the use of combined systems when compared to controls 
(oral drug solutions, results in Table 2).
The PLGA NP improvements may come as well from a micro 
matrix strategy. Nassar et al. (Nassar et al., 2011) used docetaxel-
loaded PLGA nanocapsules in entero-coated microparticles. The 
microcarrier released NPs that penetrated the enterocytes of 
rats, bypassed permeability-glycoprotein pump, and apparently 
circumvented gut metabolism of the drug. An oral administration 
of NP-in-matrix resulted in higher bioavailability than intravenous 
solution of the free drug (commercial formulation, 276%) and 
its NP formulation (400%). A subsequent study with minipigs 
confirmed the pattern obtained with rats; the superiority of NP-in-
matrix over NPs was attributed to lymphatic transportation that 
changed drug biodistribution (Attili-Qadri et al., 2013).
Lipidic NPs
Lipid NPs are well-established DDSs due to their high 
biocompatibility, biodegradability, low toxicity, and applicability 
to various administration routes (Chime and Onyishi, 2013; 
Wissing et al., 2004; Shastri, 2017; Teixeira et al., 2017; Puri 
et  al., 2009). The main lipid NPs reported are liposomes, solid 
lipid nanoparticles (SLNs), nanostructured lipid carriers, and 
nanoemulsions. The hydrophobic cores enhance drug solubility 
and protect it from the environment; the surfactant layer separates 
particles by steric or electrical hindrance. The exception is the 
liposome vesicle form, which allows loading of hydrophobic 
and hydrophilic drug molecules into its outer layer or aqueous 
core, respectively (Karamanidou et al., 2016). Among the cited 
particles, only NLC did not present in vivo data, probably because 
it is the most recent development among this group.
Lipidic NPs may deform under mechanical stress, such 
as tableting; they can also undergo lipid phase transitions 
upon heating, such as for film casting. Therefore, Hazzah et al. 
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TABLE 2 | Pharmacokinetic data for NP-in-matrix systems.
References Matrix type Matrix excipients NP-Type NP excipients Drug Pharmacokinetics
(Al-Dhubiab et al., 
2015)
Film HPMC K15 + 
Carbopol 974P + 
Eudragit® RL 100 




PLGA Acyclovir • Model: male white rabbits.
• Administration: NP-in-buccal film (1 cm2) was wetted and applied to 
the buccal mucosa for 4 h; control animals received oral drug solution 
(1 mg dose, 1 mL).
• Data for control (oral solution):
Cmax = 91.61 (ng/mL);
tmax = 2 h;
AUC∞ = 395.21 ng·h/mL.
• Data for buccal combined system (A3):
Cmax = 306.04 (ng/mL);
tmax = 6 h;
AUC∞ = 3116.21 ng·h/mL. 
(Nekkanti et al., 
2009)**
Tablet Mannitol Nanocrystal HPMC Cardesan • Model: male Wistar rats.
•Administration: oral suspensions of spray dried drug microparticles 
or drug nanoparticles at a 10 mg/kg dose.
• Data for drug microparticles:
Cmax = 0.16 ± 0.10 µg/mL;
tmax = 1.81 ± 1,13 h;
AUC∞ = 0.31 ± 0.07 ng·h/mL;
• Data for drug nanoparticles:
Cmax = 0.09 ± 0.03 µg/mL
tmax = 1.06 ± 0.38 h
AUC∞ = 0.78 ± 0.22 µg·h/mL.
(Rana and Murthy 
2013)
Patch (triple layer 
patch)
HPMC + carbopol + 
ethyl cellulose
Nanocrystals PVA Carvedilol • Model: rabbits
• Administration: NP-in-film (combined system) in a 250 µg/kg dose 
and oral tablet (control) in a 1 mg/kg dose.
• Data for control:
Cmax = 48.73 ± 14.1 ng/mL;
tmax = 2 h;
AUC∞ = 1813.70 ± 42.53 ng·h/mL.
• Data for combined system:
Cmax = 356.91 ± 29.5 ng/mL;
tmax = 4 h;
AUC∞ = 4154.37 ± 80.22 ng·h/mL.








Sodium alginate + 
Eudragit® RS100
Carvedilol • Model: male New Zealand rabbits.
• Administration: NP-in-buccal gel (3.125 mg of drug) was applied 
to the mucosa; control animals received equivalent oral dose of 
commercial tablet.
• Data for FG1 (4% HPMC K4M):
Cmax = 102.27 ng/mL
tmax = 1h
AUC0-∞ = 639.38 ng·h/mL
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TABLE 2 | Continued
References Matrix type Matrix excipients NP-Type NP excipients Drug Pharmacokinetics
• Data for FG2 (4% HPMC K4M + 2% sodium 
carboxymethylcellulose):
Cmax = 187.41 ng/mL
tmax = 1h
AUC0-∞ = 830.59 ng·h/mL
Relative bioavailability = 130.3% increase compared to the market 
product
• Data for control (commercial tablet):
tmax = 1.5 h
Exact values for Cmax and AUC are not available.




Silica Cinnarizine • Model: male Sprague-Dawley rats
• Administration: one of four formulations at 10 mg/kg via oral 
gavage (unformulated cinnarizine; silica–lipid hybrid (SLH); pluronic-
functionalized silica–lipid hybrid (PLU-SLH); NP-in-microparticle 
structure and PLU&SLH physical mixture).
• Unformulated cinnarizine:
Cmax = 262 ± 41 ng/mL;
tmax = 0.6 ± 0.1 h;
AUC∞ = 656 ± 64 ng·h/mL
• SLH:
Cmax = 258 ± 23 ng/mL;
tmax = 1.0 ± 0.0 h;
AUC∞ = 859 ± 133 ng·h/mL
• PLU-SLH:
Cmax = 427 ± 5 ng/mL;
tmax = 1.3 ± 0.3 h;
AUC0-α = 1400± 135 ng·h/mL
• PLU&SHL:
Cmax = 326 ± 39 ng/mL;
tmax = 1.1 ± 0.3 h;
AUC∞ = 971 ± 161 ng·h/mL
(Lv et al., 2015) Film Carboxymethyl 
chitosan (CCS)




• Model: healthy male rabbits.
•Administration: films applied to buccal mucosa. CCS-films containing Cu 
B loaded phospholipid–sodium deoxycholate–mixed micelles (PL-SDC-
MMs), conventional CCS (C-CCS) films and the conventional tablet 
(Hulusupian), 1 mg/kg. The tablet was administered as oral suspension.
• Data for micelles-in-CCS films:
Cmax = 2.04 ± 0.50 (µg/mL);
tmax = 5.03 ± 0.34 h;
AUC0–36 =  46.43 ± 5.11 (µg∙h/mL).
• Data for CCS films:
Cmax = 0.52 ± 0.37 (µg/mL);
tmax ~7.96 ± 0.97 h
AUC0–36 = 4.44 ± 1.21 (µg∙h/mL).
• Data for Cu B marked tablet:
Cmax = 3.08 ± 0.52 (µg/mL);
tmax = 3.01 ± 0.82 h;
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TABLE 2 | Continued
References Matrix type Matrix excipients NP-Type NP excipients Drug Pharmacokinetics
(Lv et al., 2014) Fast-dissolving 
oral films (FDOFs)
Pullulan and PEG 
400
Micelle Phospholipid (PL) 




• Model: male Wistar rats.
• Administration: Cu B-PL/SDC-MMs, the FDOFs containing Cu 
B-PL/SDC-MMs, and the Cu B suspension, all corresponding to a 
dose of 2 mg/kg.
• Data for Cu B suspension:
Cmax = 3.23 ± 0.64 (µg/mL);
tmax = 3.01 ± 0.44 h;
AUC(0–24) = 17.13 ± 3.54 (µg∙h/mL).
• Data for Cu B-PL/SDC-MMs:
Cmax = 7.18 ± 1.08 (µg/mL);
tmax = 0.69 ± 0.32 h;
AUC(0–24) = 42.25 ± 5.91 (µg∙h/mL).
• Data for Cu B-PL/SDC-MMs-in-FDOFs:
Cmax = 7.82 ± 1.21 (µg/mL);
tmax = 0.67 ± 0.28 h;
AUC(0–24) = 45.11 ± 6.13 (µg∙h/mL).
(Augustine et al., 
2018)*
Microparticle Alginate + chitosan Nanosuspension Alginate Darunavir/ritonavir • Model: albine Sprague-Dawley rats.
• Administration: 25 mg/kg dose of daruvanir + ritovanir. Groups: 
unformulated drug, the nanonized drug and the NP-in-microparticle 
loaded drug (NiMDS).
• Data for the unformulated drug:
Cmax = 0.14 µg/mL;
tmax = 2.63 h;
AUC last = 1.17 µg∙h/mL;
• Data for nanonized drug:
Cmax = 0.11 µg/mL;
tmax = 1.75 h;
AUC last = 1.35 µg∙h/mL;
• Data for NiMDS:
Cmax = 0.38 µg/mL;
tmax = 2.75 h;
AUC last = 2.67 µg∙h/mL.
(Kevadiya et al., 
2018)
Oral strip films 
(OSFs)
HPMC Nanocrystals SDS and HPMC Fenofibrate (FNB) • Model: New Zealand white rabbits.
• Administration: orally/buccal dose equivalent of 30 mg/kg of 
FNB. Groups: marketed formulation (oral suspension); pristine FNB 
(suspension); OSFs (5.28 mg/cm2 of FNB-NC-D).
• Tricor:
Cmax = 23.1 ± 8.8 µg/mL;
tmax =  8.0 ± 3.0 h;
AUC∞ = 654.6 ± 251 µg·h/mL.
• FNB:
Cmax = 16.8 ± 12.2 µg/mL;
tmax = 8.0 ± 5.8 h;
AUC∞ = 514.8 ± 374 µg·h/mL.
• FNB-NC-D:
Cmax = 37.6 ± 10.6 µg/mL;
tmax = 6.0 ± 1.7 h;
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TABLE 2 | Continued
References Matrix type Matrix excipients NP-Type NP excipients Drug Pharmacokinetics













Finasteride (FSD) • Model: healthy male volunteers.
• Administration: group I: FSD-SNELTs; group II: FSD-LTs; group III: 
FSD-marketed tablets (Proscar®), containing 5 mg of FSD.
• Data for FSD-SNELTs:
Cmax = 44.635 ± 3.259 (ng/mL);
tmax = 1.5 ± 0.289 h;
AUC last = 721.662 ± 55.085 (ng∙h/mL).
• Data for FSD-LTs:
Cmax = 37.794 ± 1.405 (ng/mL);
tmax = 2 ± 0 h;
AUC last = 444.08 ± 37.283 (ng∙h/mL).
• Data for marketed tablets:
Cmax = 29.150 ± 4.798 (ng/mL);
tmax = 3 ± 1 h;
AUC last = 487.639 ± 42.989 (ng∙h/mL).




Alginate + chitosan 
coated or not with 
Eudragit
Nanocrystal Not mentioned Indinavir • Model: mongrel dogs.
• Administration: a single dose of 10 mg/kg of: indinavir (IDV) free 
base, pure IDV nanoparticles and NP-in-microparticle delivery system 
(NiMDSs); all encapsulated within gastro-resistant capsules.
• IDV base:
Cmax = 0.34 µg/mL;
tmax = 1.10 h;
AUC∞ = 0.83 µg·h/mL;
• IDV nanoparticles:
Cmax = 1.41 µg/mL;
tmax = 2.00 h;
AUC∞ = 18.16 µg·h/mL;
• NiMDSs:
Cmax = 0.50 µg/mL;
tmax = 1.80 h;
AUC∞ = 39.23 µg·h/mL.












• Model: white New Zealand male rabbits.
• Administration: group 1: TP (0.5×0.5 cm) containing lignocaine base 
(LB) (0.872 mg/kg) and DDEA (1.6248 mg/kg) placed over the anterior 
mandibular gingiva for 12 hours. Group 2 (control): marketed Lig HCl 
gel (1.008 mg/kg) over the anterior mandibular gingiva and marketed 
diclofenac (Dic) sodium administered orally as 1.4 mg/kg. In both groups, 
the dose maintained was 0.872 mg/kg of Lig and 1.3033 mg/kg of Dic. 
• Data for TP:
- Gingival crevicular fluid (GCF):
Cmax = 0.4428 ± 0.28 (µg/mL) (Lig) and 4.6213 ± 0.21 (µg/mL) (Dic);
tmax = 0.25 h (Lig) and 2 h (Dic);
AUC∞ = 1.6396 ± 1.02 µg∙h/mL (Lig) and 808.835 ± 3.25 µg∙h/mL (Dic).
- Plasma:
Cmax = 0.3259 ± 0.03 (µg/mL) (Lig) and 0.1910 ± 0.02 (µg/mL) (Dic);
tmax = 1 h (Lig) and 2 h (Dic);
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• Data for control:
- Gingival crevicular fluid (GCF):
Cmax = 0.0499 ± 0.02 (µg/mL) (Lig) and 1.6495 ± 0.05 (µg/mL) (Dic);
tmax = 0.5 h (Lig) and 2 h (Dic);
AUC∞ = 0.1024 ± 0.31 µg∙h/mL (Lig) and 8.6204 ± 0.22 µg∙h/mL (Dic).
- Plasma:
Cmax = 0.1645 ± 0.01 (µg/mL) (Lig) and 1.4181 ± 0.15 (µg/mL) (Dic);
tmax = 0.5 h (Lig) and 2 h (Dic);
AUC∞ = 0.6568 ± 0.01 µg∙h/mL (Lig) and 4.6808 ± 0.26 µg∙h/mL (Dic).
(Guo et al., 2015)** Tablet Not mentioned Nanocrystals Pluronic F68, HPMC 
K4M, HPMC E5, PVP 
K30
Rebamipide (REB) • Model: male Sprague-Dawley rats
• The test preparation rebamipide nanocrystal tablets (REB-NTs) were 
compared with that of a reference formulation of Mucosta® tablets 
(REB-MTs). Dose = 10 mg/kg.
• REB-Nts:
Cmax = 543.4 ± 150.5 ng/mL;
tmax = 1.67 ± 0.41 h;
AUC∞ = 2622.3 ± 462.8 ng·min/mL.
• REB-Mts:
Cmax = 281.5 ± 66.1 ng/mL;
tmax = 1.08 ± 1.34 h;
AUC∞ = 1187.4 ± 411.8 ng·min/mL.







Self-nanoemulsion Surfactants (Tween 
80 and Cremophore 
RH 40), oils (oleic 
acid, labrafac, labrafil) 
and cosurfactant 
(propylene glycol)
Rosuvastatin • The study was performed in healthy male volunteers.
• Administration: SNE-tablet and Crestor®; the tablets were 
administered orally at a dose of 10 mg each.
• Data for Crestor®:
Cmax = 23 885 (ng/mL);
tmax = 3 h;
AUC last = 264 210 (ng∙h/mL).
• Data for SNE tablet:
Cmax = 66 521 (ng/mL);
tmax = 2 h;
AUC last = 648 219 (ng∙h/mL).
(Al-Dhubiab, 2016a) Buccal Film HPMC K15 + 
Carbopol 971P + 
Eudragit® RS 100 




PLGA/PVA Selegiline • Model: male white rabbits.
• Administration: NP-in-buccal film (1 cm2) was wetted and applied to 
the buccal mucosa for 4 h; control animals received oral drug solution 
(1 mg dose, 1 mL).
• Data for control (oral drug solution):
Cmax = 264.28 (ng/mL);
tmax = 1 h;
AUC∞ = 877.07 ng·h/mL.
• Data for buccal film (F3):
Cmax = 426.58 (ng/mL);
tmax = 4 h;
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Vitamin K • Model: male human volunteers.
•Administration: subjects were classified into 3 groups (6 per each). 
Group I: vitamin K-in-SNELTs; group II: commercial tablet; group III: 
injected drug ampoule intramuscularly. All groups = 10 mg.
• Data for vit K-in-SNELTs:
Cmax = 1572.37 ± 120.2 (ng/mL);
tmax = 2.5 ± 0.0 h;
AUC last = 7283.34 ± 85.4 (ng∙h/mL).
• Data for commercial tablet:
Cmax = 1054.97 ± 91.04 (ng/mL);
tmax = 3.0 ± 0.0 h;
AUC last = 4379.59 ± 202.3 (ng∙h/mL).
• Data for intramuscular drug ampoule:
Cmax = 1868.28 ± 89.2 (ng/mL);
tmax = 2.0 ± 0.0h;
AUC last = 8379.76 ± 1434.7 (ng∙h/mL).
(Al-Dhubiab, 2016b) Film HPMC K100 + 




PLGA Zolpidem • Model: male white rabbits.
• Administration: NP-in-buccal film (1 cm2) was wetted and applied to 
the buccal mucosa for 4 h; control animals received oral drug solution 
(1 mg dose, 1 mL).
• Data for control (oral drug solution):
Cmax = 32.34 (ng/mL);
tmax = 1 h;
AUC∞ = 136.06 ng·h/mL.
• Data for buccal film (Z4):
Cmax = 52.54 (ng/mL);
tmax = 1.5 h;
AUC∞ = 236.00 ng·h/mL.








and Transcutol HP 
(cosurfactant)
Vitamin K1 (VK1) • Model: beagle dogs.
•Administration: six healthy beagle dogs randomly divided into two 
groups (SNE-L tablets and conventional VK1 tablets), receiving a 
single 10 mg oral dose.
• Data for combined system:
Cmax = 575.46 ± 84.27 (ng/mL);
tmax = 1.67 ± 0.58 h;
AUC∞ = 1716.33 ± 264.20 (ng∙h/mL).
• Data for control (commercial tablet):
Cmax = 249.23 ± 79.05 (ng/mL);
tmax = 2.0 ± 1.0 h;
AUC∞ = 866.14 ± 215.45 (ng∙h/mL).
(Attili-Qadri et al., 
2013)
Microparticle Eudragit L + HPMC Polymeric 
(nanocapsule)
Glyceryl 
tributyrate + oleoyl 
polyoxylglycerides + 
PLGA
Docetaxel • Model: minipigs.
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• Data for control (oral solution of commercial drug):
Cmax = 97.6 (ng/mL);
AUC∞ = 797.7 ng·h/mL.
• Data for combined system:
Cmax = 817.9 (ng/mL);
AUC∞ = 7,923.1 ng·h/mL.
(Nassar et al., 
2011)*
Microparticle Eudragit L + HPMC Polymeric 
(nanocapsule)
Glyceryl 
tributyrate + oleoyl 
polyoxylglycerides + 
PLGA
Docetaxel • Model: Sprague-Dawley male rats
• Administration: intravenous dose of drug-loaded NPs and oral dose 
of combined system (5mg/kg).
• Data for drug-loaded NPs:
AUC = 1,441.9 ng·h/mL.
• Data for oral combined system:
AUC = 5,754.5 ng·h/mL
(Soudry-Kochavi 
et al., 2015)**
Microparticle Eudragit L + HPMC Polymeric 
(nanosphere)
BSA + dextran 
+ sodium 
trimetaphosphate
Exenatide • Model: Sprague-Dawley male rats.
• Administration: drug solution and commercial drug (Byetta™) were 
administered subcutaneously (SC)(65µg/kg). Combined systems 
DX-50 and DX-150 were administered orally (by gavage) (165 µg/kg).
• Data for control (SC commercial drug):
Cmax = 1.22 µg/mL
tmax = 1.33 h
AUC = 31.01 h∙µg∙10-2/mL.
• Data for control (SC drug solution):
Cmax = 1.06 µg/mL
tmax = 0.83 h
AUC = 26.37 h∙µg∙10-2/mL.
• Data for oral combined system DX-50 (50 mg dextran):
Cmax = 2.09 µg/mL
tmax = 1.33 h
AUC = 59.45 h∙µg∙10-2/mL.
• Data for oral combined system DX-150 (150 mg dextran):
Cmax = 1.80 µg/mL
tmax = 1.00 h
AUC = 36.00 h∙µg∙10-2/mL.
NP, nanoparticle; AUC, area under the curve that describe drug concentration over time, measured in plasma; Cmax, the maximum drug concentration measured in plasma; tmax, the time taken to reach the maximum drug 
concentration; PVA, polyvinyl alcohol; PLGA, poly(lactic-co-glycolic acid); HPMC, hydroxypropyl methylcellulose; PEG, polyethylene glycol; SDS, sodium dodecyl sulfate; PVP, polyvinylpyrrolidone; BSA, bovine serum albumin.
*Studies comparing pharmacokinetic data for NP-in-matrix and free NPs.
**NP-in-matrix systems for oral delivery.
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to avoid the cited issues. Human studies showed that curcumin 
SLN-in-polycarbophil sponge has higher Cmax, tmax, and AUC 
than the SLN-in-HPMC sponge (Table 2). In accordance, 
polycarbophil formulation adhered to the mucosa for a longer 
time (15 h, compared to 4 h) and presented higher matrix 
porosity and homogeneous distribution of SLNs. The decreased 
porosity of HPMC sponges diminished swelling and consequent 
interaction with mucin. Also, SLNs remained onto the surface of 
HPMC sponges, lowering its adhesion property to the oral mucosa 
and releasing the NPs faster than polycarbophil. Although pure 
NPs were not tested in vivo, in vitro release showed that NP-in-
sponge eliminated the burst effect of the nanodispersions, which 
improves prediction of therapy outcomes and avoids possible 
plasma peaks (Hazzah et al., 2015).
Ahmed et al. also used freeze-dried polymeric matrix (gelatin 
“tablets,” no compression step) to load lipidic self-nanoemulsions 
(SNEs) of finasteride. Different from the mucoadhesive sponges, 
the freeze-dried tablets melt on the mouth upon contact with 
saliva. These macrocarriers aim as fast release as possible for 
buccal and gastrointestinal absorption. Both formulated tablets 
(with or without SNE) presented in human higher Cmax and 
shorter tmax of the drug than the marketed tablets. Likewise, 
AUC and Mean Residence Time (MRT) indicated superiority 
of NP-in-tablet system. The improved drug bioavailability may 
enhance the therapeutic effects (Ahmed et al., 2018).
A variety of this technique decreased the low bioavailability 
of oral vitamin K. The SNE was loaded on porous silica carriers 
and later incorporated in lyophilized tablets. SNE-in-lyophilized 
tablets increased absorption rate and extent of vitamin K in 
humans compared to marketed tablets. Even better, the NP-in-
matrix system presented AUC similar to the commercial 
intramuscular injection (El-Say et al., 2017). Powdered SNE 
loaded with vitamin K1 was also incorporated into regular 
tablets, but with different vitamin loadings. Because SNEs 
form nanoparticles upon contact with gastrointestinal fluid, 
NP deformation was not a concern. Beagle dogs administered 
with SNE-in-tablet showed a 2.3-fold increase in vitamin K1 
Cmax and 1.98-fold in AUC (Tong et al., 2018). The increment in 
bioavailability probably happened due to higher surface area and 
consequent higher drug dissolution rate in the gastrointestinal 
tract (Gong et al., 2016).
SNE-in-tablet was also applied to rosuvastatin delivery, 
increasing solubility and bypassing hepatic first-pass metabolism. 
Male humans taking SNE-in-tablet had rosuvastatin AUC 
increased 2.45 times and Cmax increased 2.78 times compared 
with the intake of commercial rosuvastatin tablets. Similarly, tmax 
decreased with drug administration in SNE tablet, highlighting 
its benefits (Salem et al., 2018).
The latter lipid NP-in-matrix with published in vivo 
pharmacokinetics is the phospholipid-bile salts-mixed micelles. 
Cucurbitacin B was loaded in these micelles to address its water 
insolubility, toxicity, and gastrointestinal side effects. The use 
of fast-dissolving oral films of pullulan as a matrix maintained 
the in vivo absorption properties like micelles and promoted a 
significant increase in the oral bioavailability of cucurbitacin B in 
Wistar rats (highest values of Cmax and AUC, lowest tmax), when 
compared to the free suspension drug. Also, the matrix did not 
interfere with Cu B-micelles original structure (Lv et al., 2014). 
These micelles in carboxymethyl chitosan buccal film rendered a 
mucoadhesive formulation, which released the drug for a longer 
period. It resulted in 2.69-fold increase in bioavailability in rabbits 
when compared to marketed tablets and 10.46 times the film 
formulation without NP. The team reported that buccal mucosa 
barrier probably explains higher Cmax and lower tmax of oral tablets; 
high AUC from film formulations may be owed to the presence 
of permeation enhancers in it and the nanosized drug, ensuring 
the increase in the amount of drug penetration into the blood (Lv 
et al., 2015). It would be interesting to compare the influence of 
the different matrices in cucurbitacin B kinetics, but the animal 
models differ in species, drug dose, and period of evaluation.
Inorganic NPs
Inorganic nanoparticles are flexible carriers that allow surface 
modification, drug targeting, and modified drug release. This 
group includes silica, clay, and metals as excipients arranged 
in nanoparticles, nanotubes, or nanorods/nanoparticles, 
respectively (Kerdsakundee et al., 2017; Rao et al., 2011; Zhang 
et al., 2018). The silica-based ones were the only inorganic NP-in-
matrix compositions tested in vivo for oral administration. 
Although biocompatible and with a well-defined/modifiable 
structure, they do not adhere to mucosa and are good candidates 
for matrix incorporation (Slowing et al., 2008).
To improve the oral delivery of the poorly soluble drug 
cinnarizine, an antihistamine and calcium-channel blocker, 
Rao S. et al. developed a pluronic functionalized silica–lipid 
hybrid microparticle. Pluronic acts as a polymeric precipitation 
inhibitor, avoiding recrystallization of cinnarizine dissolution; 
the silica–lipid hybrid microparticle improved drug partition by 
producing a hydrophobic microenvironment. Bioavailability was 
compared between the cinnarizine loaded functionalized silica-
lipid hybrid system, unformulated cinnarizine and a cinnarizine 
loaded nonfunctionalized silica-lipid system; the in vivo design 
included a single dose of 10 mg/kg of each formulation via oral 
gavage. The study resulted in more than 2.1-fold improvement 
in the AUC and 1.6-fold improvement in Cmax of cinnarizine of 
the functionalized NP-in-microparticle structure in comparison 
to the unformulated one and a 1.6-fold improvement in both 
AUC and Cmax in comparison with the nonfunctionalized 
formulation, resulting in an overall improved bioavailability of 
cinnarizine (Rao et al., 2015).
Drug-Based NPs
Poor solubility, low bioavailability, and short stability in vivo 
are limiting problems in the development and delivery of new 
active ingredients (Liu et al., 2012). To overcome these issues, 
one can entrap the drug in a nanocarrier or reduce its particles 
to obtain a nanosized range, such as nanocrystals. Compared 
to NPs, drug-based particles offer higher drug loading (nearly 
100%) with generally less excipients and uniform/stable physical 
nature (Liu et al., 2012).
Accordingly, indinavir nanonization increased absorption 
(from 0.83 to 18.16 µg∙h/mL) and tmax (from 1.10 to 2.50 h) of 
the free base drug after administration of a single oral dose in 
mongrel dogs; however, NP-in-microparticle alginate/chitosan 
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particles performed much better than pure nanocrystals (AUC 
of 39.23 µg∙h/mL and t½ value of 76.3 h). This represented an 
increase of the oral bioavailability and the apparent t½ of 47 and 
95 times, compared to the free drug. The increment in release 
time may improve HIV treatment, which demands long-term 
therapy and frequent dosing (Imperiale et al., 2015). Likewise, 
darunavir and ritonavir benefited from an NP-in-microparticle 
oral delivery system for nanocrystals. The difference was that 
NP-in-microparticle increased the oral bioavailability of the 
combined drugs by 2.3-fold compared with the NP only and 
the free drug. In this case, nanonization alone was not able to 
increase absorption (Augustine et al., 2018).
Nanocrystals vehicled in tablets and buccal films allow 
easier self-administration, increased dosage precision, and 
superior performance. Rebamipide presents only 10% of oral 
bioavailability in humans due to poor solubility, which is the 
reason Guo and coworkers formulated an NP-in-tablet version of 
the medicine. Drug nanocrystals were stabilized with HPMC and 
polyvinylpyrrolidone before tablet incorporation. The relative 
oral bioavailability of REB nanocrystal tablets was 256.8% in 
rats (reference Mucosta® tablets) (Guo et al., 2015). Nekkanti’s 
group also used HPMC-stabilized nanocrystals for candesartan 
cilexetil delivery, further incorporated in mannitol-based tablets. 
This prodrug belongs to the low solubility/long-term therapy 
group, such as rebamipide. In vivo studies confirmed dosage 
form benefits: Wistar rats presented 2.51-fold increase in AUC, 
a 1.77-fold increase in Cmax, and a decreased tmax (1.81–1.06 h) 
compared to the free prodrug (Nekkanti et al., 2009).
Rana and Murthy developed a three-layer buccal film: a 
mucoadhesive layer, a layer containing nanosuspension of carvedilol 
nanocrystals and a backing membrane. The structure aimed to 
prevent the first-pass metabolism, raising drug bioavailability. Cmax 
of the buccal patch was 7.3 times higher than that of the oral tablet, 
and tmax exhibited by the patch was 4 h in comparison to 2 h for oral 
tablet. The NP-in-microparticle structured buccal patch has been 
designed as a novel platform for potential buccal delivery of drugs 
having high first-pass metabolism (Rana and Murthy, 2013).
Another application of nanosized drugs is the development of 
better suitable dosage forms of existing drugs to attend the patient 
needs. Kevadiya et al. developed an oral strip-film containing 
nanocrystals of the cholesterol-reducing agent fenofibrate, a very 
low solubility prodrug, aiming to create a fast disintegrating solid 
dosage form ideal for emergency administration and for patients 
with swallowing difficulties. New Zealand white rabbits were 
divided in three groups: the first received the oral commercial 
formulation Tricor in suspension form; the second received 
the suspension of fenofibrate nanocrystals (pristine FNB) and 
the third received the oral striped-films containing fenofibrate 
nanocrystals (OSF). Pharmacokinetics data showed a higher Cmax 
and lower tmax of OSF when compared to the marketed Tricor 
formulation and pristine FNB. The AUC was also higher for OSF 
formulation (931.26 µg·h/mL) compared to Tricor (654.6 ± 251 
µg·h/mL) and pristine FNB (514.8 ± 374 µg·h/mL); and the tmax 
(h) of OSFs was found to be 2 h earlier than the tmax of Tricor and 
pristine FNB (Kevadiya et al., 2018).
CONCLUSION
Because most of the articles we gathered date from this decade, 
NP-in-matrix approach still has a long way for exploitation. In 
our findings, most matrices belong to the polymeric group, based 
on classical excipients in the market, like HPMC. However, they 
vary from buccal to oral delivery, with rapid or slow degradation 
to offer an immediate or modified release. The use of an external 
matrix to incorporate nanoparticles brought several advantages 
to formulations. This type of system reduced burst effect, avoided 
NP degradation in gastrointestinal tract, increased residence time 
in the mouth, modulated tmax, and bypassed first-pass metabolism 
(buccal forms and some oral forms). Thus, the systemic 
bioavailability of the tested drugs was successfully enhanced.
Buccal release belongs to the trending strategies for drugs, so 
we expect an increase in pharmacokinetic studies concerning 
NP-in-matrix buccal delivery. Nanoparticle types will probably 
expand too, as the actual group is mainly PLGA, nanocrystals, 
and some lipid particles. In summary, we believe this article 
compiled several evidences and possible pitfalls of this strategy, 
which will help future developments on the field.
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